Novel biomarkers for non-invasive identification/warning of fatty liver in dairy cows

A biomarker, fatty liver disease technology, applied in the fields of analytical chemistry and clinical medicine, can solve problems such as unfavorable animal welfare, poor prognosis and complicated infectious diseases, and achieve the effect of high diagnostic application value, low cost and simple operation.

CN110501443BActive Publication Date: 2020-09-29SHANDONG AGRICULTURAL UNIVERSITY
6 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Publication Date
2020-09-29

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a set of novel non-invasive biomarkers to identify dairy cows with fatty liver disease, setting up a pre-warning system and method. The biomarkers are: L-a aminobutyric acid and Behenic acid in feces, and 3-Nitrotyrosine in urine. It is validated that the AUC value of each of the above biomarkers is higher than that of the traditional serum biochemical indicators commonly used in clinical, indicating the three novel biomarkers have higher diagnostic ability. Moreover, the combined diagnostic results of the three biomarkers show a higher diagnostic application value. Application of these novel biomarkers in production of dairy industry will accurately identify the dairy cows with fatty liver and also monitor the health situation of cow population, but also simplify the diagnostic steps and lower the diagnostic cost, because of escape of liver biopsy and / or blood collection. This benefits for animal welfare, and also is supportive for the sustainable development of dairy industry. Additionally, it will be helpful for the selection of bulls and dams in breeding.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical fields of analytical chemistry and clinical medicine, in particular to a novel biomarker for non-invasive identification / early warning of fatty liver cows. Background technique

[0002] The normal liver contains about 5% fat (calculated by wet weight). When some reason or many reasons affect the fat metabolism process in the liver, and the fat accumulates in the liver beyond the normal content of the liver, it is called fatty liver. Steatosis occurs in the intrahepatic cells, and histology shows that the cytoplasm of the hepatocytes is full of fat droplets. The disease often occurs postpartum in dairy cows, and is more frequent in high-yielding dairy cows. Fatty liver disease in dairy cows is one of the metabolic disorders that often occur in dairy cows during the peripartum period. In severe cases, it can also cause ketosis and postpartum paralysis, which seriously affects the milk production performance, reprod...

Examples

Embodiment 1

[0057] Example 1: Screening and Discovery of Candidate Markers - Screening and Discovery of Differential Metabolite Markers in a Liver Biopsy Diagnostic Population

[0058] First, 18 dairy cows were selected as the Discovery set, and were divided into normal group (n=8) and diseased group (n=10) through liver tissue biopsy. The feces and urine of dairy cows were collected, and detected by mass spectrometry Differential distribution of molecular metabolites in normal and diseased groups. The model detection of metabolites showed that the distribution of differences between the two groups was significant, and the model was reliable. Differential markers were screened by two statistical analysis methods: VIP (Variable importance in projection) multidimensional test, with VIP>1 and P figure 2 ); single-dimensional T test, with P image 3 ), take the intersection of the candidate markers screened by the two methods ( Figure 4 ), and finally get the candidate difference markers of ...

Embodiment 2

[0059] Example 2: Screening of potential biomarkers - verification of differential expression of candidate markers in other groups of individuals

[0060] Select 16 dairy cows as the Test set, the purpose is to verify the candidate differential markers of the Discovery set through an independent sample group; through the results of traditional clinical serum indicators, B-ultrasound fluoroscopy and comprehensive veterinary diagnosis, it is divided into suspected Normal group (n=7) and suspected disease group (n=9), collect feces and urine, according to the method identical with embodiment 1:: VIP (Variable importance in projection) multidimensional test ( Figure 5 ), one-dimensional T-test ( Image 6 ), take the intersection of the candidate markers screened by the two methods ( Figure 7 ) for mass spectrometry detection of small molecule metabolites, statistical analysis, and finally screened out the candidate differential markers of the Test set.

[0061] Compare the can...

Embodiment 3

[0066] Example 3: Validation of identification capability of 3 potential biomarkers - violin plot and ROC curve.

[0067] The violin plot shows ( Figure 8 ), compared with normal cows, L-Alpha-aminobutyric acid in feces and 3-Nitrotyrosine in urine were significantly down-regulated, while Behenic acid in feces was significantly up-regulated. ROC curve analysis shows that (such as Figure 9-Figure 11 ), the AUC value of each marker is higher than that of traditional clinical biochemical indicators, and has higher clinical diagnostic application value; moreover, the combined diagnostic results of the three fecal and urinary biomarkers show higher diagnostic application value ( The AUC value can reach 0.988, Table 2).

[0068] In the application of dairy farming, by detecting the relative content of these three biomarkers in cow feces or urine, dairy cows with potential fatty liver disease can be identified and detected. This biomarker provides a new technology and method for...